These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36484997)

  • 1. An Activity-Based Oxaziridine Platform for Identifying and Developing Covalent Ligands for Functional Allosteric Methionine Sites: Redox-Dependent Inhibition of Cyclin-Dependent Kinase 4.
    Gonzalez-Valero A; Reeves AG; Page ACS; Moon PJ; Miller E; Coulonval K; Crossley SWM; Xie X; He D; Musacchio PZ; Christian AH; McKenna JM; Lewis RA; Fang E; Dovala D; Lu Y; McGregor LM; Schirle M; Tallarico JA; Roger PP; Toste FD; Chang CJ
    J Am Chem Soc; 2022 Dec; 144(50):22890-22901. PubMed ID: 36484997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
    Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
    PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
    Bockstaele L; Bisteau X; Paternot S; Roger PP
    Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation.
    Knight H; Abis G; Kaur M; Green HLH; Krasemann S; Hartmann K; Lynham S; Clark J; Zhao L; Ruppert C; Weiss A; Schermuly RT; Eaton P; Rudyk O
    Circ Res; 2023 Dec; 133(12):966-988. PubMed ID: 37955182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.
    Colleoni B; Paternot S; Pita JM; Bisteau X; Coulonval K; Davis RJ; Raspé E; Roger PP
    Oncogene; 2017 Jul; 36(30):4349-4361. PubMed ID: 28368408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27.
    Coulonval K; Vercruysse V; Paternot S; Pita JM; Corman R; Raspé E; Roger PP
    Cell Cycle; 2022 Jan; 21(1):12-32. PubMed ID: 34913830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in applications of activity-based chemical probes in the characterization of amino acid reactivities].
    Li J; Wang G; Ye M; Qin H
    Se Pu; 2023 Jan; 41(1):14-23. PubMed ID: 36633073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes.
    Ray A; James MK; Larochelle S; Fisher RP; Blain SW
    Mol Cell Biol; 2009 Feb; 29(4):986-99. PubMed ID: 19075005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase.
    Paternot S; Bockstaele L; Bisteau X; Kooken H; Coulonval K; Roger PP
    Cell Cycle; 2010 Feb; 9(4):689-99. PubMed ID: 20107323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
    Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
    Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
    Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
    Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NHS-Esters As Versatile Reactivity-Based Probes for Mapping Proteome-Wide Ligandable Hotspots.
    Ward CC; Kleinman JI; Nomura DK
    ACS Chem Biol; 2017 Jun; 12(6):1478-1483. PubMed ID: 28445029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4.
    Patel P; Asbach B; Shteyn E; Gomez C; Coltoff A; Bhuyan S; Tyner AL; Wagner R; Blain SW
    Mol Cell Biol; 2015 May; 35(9):1506-22. PubMed ID: 25733683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity.
    Anderson KE; To M; Olzmann JA; Nomura DK
    ACS Chem Biol; 2017 Oct; 12(10):2522-2528. PubMed ID: 28892616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4.
    Barhoover MA; Hall JM; Greenlee WF; Thomas RS
    Mol Pharmacol; 2010 Feb; 77(2):195-201. PubMed ID: 19917880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.
    Blancquaert S; Wang L; Paternot S; Coulonval K; Dumont JE; Harris TE; Roger PP
    Mol Endocrinol; 2010 Jul; 24(7):1453-68. PubMed ID: 20484410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.
    Raspé E; Coulonval K; Pita JM; Paternot S; Rothé F; Twyffels L; Brohée S; Craciun L; Larsimont D; Kruys V; Sandras F; Salmon I; Van Laere S; Piccart M; Ignatiadis M; Sotiriou C; Roger PP
    EMBO Mol Med; 2017 Aug; 9(8):1052-1066. PubMed ID: 28566333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.
    Rocha AS; Paternot S; Coulonval K; Dumont JE; Soares P; Roger PP
    Mol Biol Cell; 2008 Nov; 19(11):4814-25. PubMed ID: 18799615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.